Molecular Biology
-
In the Group for Molecular Biology we study molecular mechanisms that underlie cardiovascular, pulmonary and malignant We primarily aim to elucidate basic physiological processes and etiopathological mechanisms in these diseases, with focus on translational potential of our research. Our main interests include:
- Molecular mechanisms of various biological processes including haemostasis, inflammation, tissue remodeling and response to oxidative stress.
- Influence of gene variants and environmental factors on the phenotype.
- Identification and functional characterization of molecular markers.
- In vitro(primary and continuous cell lines) and in vivo(zebra fish) study of selected physiological and pathological interests.
Group for Molecular Biology successfully collaborates with a number of scientific research and health institutions in Serbia, as well as eminent foreign institutes. We are open to all types of cooperation.
-
GENIUS - GENETIC AND ENVIRONMENTAL INFLUENCES ON PSYCHOLOGICAL ADAPTATION OF CHILDREN AND ADULTS
ProORC - Profiling ORC genetics and regulation in cance
GREENTECH-Active substances from supercritical plant extracts for high value added products
SCIENCE ON THE MOVE - FROM LAB TO STREETS & SCHOOL (SCIENCESCOOL)
-
HEAD OF THE GROUP
- Valentina Đorđević - Full research professor
ASSOCIATE RESEARCH PROFESSOR
- Ljiljana Rakićević
- Marija Stanković
- Mila Ljujić
- Aleksandra Divac Rankov
- Branko Tomić
- Jelena Kušić-Tišma
ASSISTANT RESEARCH PROFESSOR
RESEARCH ASSISTANT
JUNIOR RESEARCHER
OTHERS
- Sara Trifunović, Researcher
-
- Alpha-1 antitrypsin expression is upregulated in multidrug-resistant cancer cells
Divac Rankov A, Jovanović Stojanov S, Dragoj M, Ljujić M
Histochem Cell Biol 2022. doi: 10.1007/s00418-022-02172-3 - Lactobacillus brevis BGZLS10-17 and Lb. plantarum BGPKM22 exhibit anti-inflammatory effect by attenuation of NF-κB and MAPK signaling in human bronchial epithelial cells
Stankovic M, Veljovic K, Popovic N, Kojic S, Dunjic Manevski S, Radojkovic D, Golic N
Int J Mol Sci 2022;23(10):5547 - Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection
Kovac M, Mitic G, Milenkovic M, Basaric D, Tomic B, Markovic O, Zdravkovic M, Ignjatovic V
Thromb Res 2022;218:151-156 - Electronic cigarette liquids impair metabolic cooperation and alter proteomic profiles in V79 cells
Trifunovic S, Smiljanić K, Sickmann A, Solari FA, Kolarevic S, Divac Rankov A, Ljujic M
Respir Res 2022;23(1):191 - Molecular Diagnostics of Cystic Fibrosis in Serbia: Our Approach to Meet the Diagnostic Challenges
Divac Rankov A, Kusic-Tisma J, Ljujic M, Nikolic A, Milosevic K, Vilotijevic Dautovic G, Radojkovic D
Genet Test Mol Biomarkers 2020;24(4):212-216 - The silence speaks, but we do not listen: synonymous c.1824C>T gene variant in the last exon of the prothrombin gene as a new prothrombotic risk factor
Pruner I, Farm M, Tomic B, Gvozdenov M, Kovac M, Miljic P, Soutari NMH, Antovic A, Radojkovic D, Antovic J, Djordjevic V
Clin Chem 2020;66(2):379-389 - Pharmacogenetics of clopidogrel therapy and neurointerventional procedures: we need precision data for precision medicine
Rakicevic L, Nestorovic A
Clin Pharmacol Ther 2019;105(3):547-549 - Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M, Matic D, Kusic-Tisma J, Antonijevic N, Radojkovic D, Rakicevic L
Eur J Clin Pharmacol 2018;74(4):443-451 - Targeting autophagy to modulate cell survival: a comparative analysis in cancer, normal and embryonic cells.
Divac Rankov A, Ljujić M, Petrić M, Radojković D, Pešić M, Dinić J
Histochem Cell Biol 2017;148(5):529-544 - Clinical and biochemical characterization of the Prothrombin Belgrade mutation in a large Serbian pedigree: new insights into antithrombin resistance mechanism
Miljic P, Gvozdenov M, Takagi Y, Takagi A, Pruner I, Dragojevic M, Tomic B, Bodrozic J, Kojima T, Radojkovic D, Djordjevic V
J Thromb Haemost 2017;15(4):670-677
- Alpha-1 antitrypsin expression is upregulated in multidrug-resistant cancer cells
-
Vojvode Stepe 444a
P.O BOX 23
11010 Beograd, SrbijaTel: +381 11 3976658
Mob:+381 65 3976658
Faks: +381 11 3975808